BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, September 30, 2023
Home » Topics » Deals and M&A

Deals and M&A
Deals and M&A RSS Feed RSS

Doing one’s homework in M&As a key to maximizing acquired product value

June 29, 2023
By Mark McCarty
No Comments
Sometimes a merger or acquisition brings a device that has a set of indications for use that cannot be practicably expanded, but Nathan Downing of Gardner Law of Stillwater, Minn., said this is not always the case. Downing said that preliminary conversations between the two parties to mergers and acquisitions can clarify a lot about whether a particular device has ample room to grow.
Read More

Conformis and Restor3d agree to merge

June 28, 2023
By Meg Bryant
No Comments
Conformis Inc. has inked a definitive agreement to be acquired by Restor3d Inc., in a move that could potentially create a formidable presence in the personalized orthopedics space. Under the agreement, Restor3d will acquire all outstanding shares of Conformis common stock (NYSE:CFMS) at $2.27 per share in cash. The purchase price represents a roughly 96% premium to Conformis’ closing price on June 22, 2023.
Read More
Urinary tract with kidneys, adrenalin glands, ureter and vessels on light blue background

Telix expands urology pipeline with $35M acquisition of Lightpoint Medical

June 27, 2023
By Tamra Sami
No Comments
Telix Pharmaceuticals Ltd. will acquire Lightpoint Medical Ltd. in a $35 million deal that will expand its urology pipeline and bring in house a new surgery-focused unit. Under the terms of the deal, Telix of Melbourne, Australia, will pay Lightpoint $20 million up front and a further $15 million on achievement of certain development milestones. The up-front payment will be paid in equity, and the additional milestones will be payable in cash or equity, at Telix’s election.
Read More
Digital handshake

Aslan signs $138.5M licensing deal with Zenyaku for atopic dermatitis drug eblasakimab in Japan

June 27, 2023
By Marian (YoonJee) Chu
No Comments
Aslan Pharmaceuticals Pte Ltd. said it inked a licensing deal with Zenyaku Kogyo Co. Ltd. for its atopic dermatitis-targeting monoclonal antibody, eblasakimab, that could reach $138.5 million in up-front and milestone payments.
Read More

Shionogi to acquire Qpex for $140M to expand antimicrobial pipeline

June 27, 2023
By Tamra Sami
No Comments
Shionogi & Co. Ltd.’s U.S. subsidiary Shinogi Inc. will acquire San Diego-based Qpex Biopharma Inc. in a deal worth up to $140 million that expands Shionogi’s pipeline of infectious disease agents and also adds to Brii Biosciences Ltd.’s pipeline.
Read More

Shionogi to acquire Qpex for $140M to expand antimicrobial pipeline

June 26, 2023
By Tamra Sami
No Comments
Shionogi & Co. Ltd.’s U.S. subsidiary Shinogi Inc. will acquire San Diego-based Qpex Biopharma Inc. in a deal worth up to $140 million that expands Shionogi’s pipeline of infectious disease agents and also adds to Brii Biosciences Ltd.’s pipeline.
Read More
Gavel and FTC logo

US FTC no longer alone in trying to stop Amgen-Horizon deal

June 26, 2023
By Mari Serebrov
No Comments
The U.S. FTC picked up six allies in its unprecedented effort to stop Amgen Inc.’s $27.8 billion acquisition of Horizon Therapeutics plc, as the attorneys general for California, Illinois, Minnesota, New York, Washington and Wisconsin joined the agency in signing onto an amended complaint filed under seal June 22 in the U.S. District Court for the Northern District of Illinois.
Read More
Digital handshake

Aslan signs $138.5M licensing deal with Zenyaku for atopic dermatitis drug eblasakimab in Japan

June 23, 2023
By Marian (YoonJee) Chu
No Comments
Aslan Pharmaceuticals Pte Ltd. said it inked a licensing deal with Zenyaku Kogyo Co. Ltd. for its atopic dermatitis-targeting monoclonal antibody, eblasakimab, that could reach $138.5 million in up-front and milestone payments.
Read More
Stock merger illustration

Merger with Talaris to advance Tourmaline’s hidden gem for TED

June 22, 2023
By Karen Carey
No Comments
Less than two years old, Tourmaline Bio Inc. is gaining a public listing through a reverse merger with publicly traded Talaris Therapeutics Inc., as it enters a phase IIb with its lead IL-6 inhibitor for thyroid eye disease (TED).
Read More
Hands holding holographic intestine

Beyond the shadow of doubt, Aeglea to a-Spyre in IBD with takeover and financing

June 22, 2023
By Randy Osborne
No Comments
Just over a month after expressing “substantial doubt that the company can continue as a going concern,” Aeglea Biotherapeutics Inc. came back from the brink with a deal to take over Spyre Therapeutics Inc. in a stock-for-stock transaction, signed concurrently with an agreement to raise $210 million via the sale of series A preferred shares.
Read More
Previous 1 2 … 8 9 10 11 12 13 14 15 16 … 194 195 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Sept. 29, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for September 29, 2023.
  • Illustration of Alzheimer’s in the brain.

    Study identifies cause of death for Alzheimer’s neurons

    BioWorld
    By creating a new mouse model of Alzheimer’s disease that better recapitulated how the disease plays out in humans, investigators at KU Leuven have gained new...
  • 3D illustration of cancer in crosshairs

    Dato data lack means upside for Gilead; Padcev 'must-win' does win

    BioWorld
    Upbeat phase III findings outweighed less encouraging late-stage trial news, as big pharma provided a mixed bag of cancer findings – with one data batch to form...
  • Apple Computer Inc. logo

    Apple scores win over Masimo for patents for physiological detectors, but ITC decision awaits

    BioWorld MedTech
    Apple Inc., of Cupertino, Calif., has prevailed over Masimo Corp., in a ruling at the U.S. Court of Appeals for the Federal Circuit, an outcome that invalidated...
BioFuture ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing